Skip to Content
NIH - National Institutes of Health National Cancer Institute Division of Cancer Treatment and Diagnosis Center for Cancer Research
NCI Experimental Therapeutics Program (NExT)
Contact NExT
Show menu
Search this site

Who is the NExT Program for?

Domestic and international researchers in academia, nonprofit, government & industry

What does the NExT Program do?

NExT is NOT a grant mechanism. Instead, NExT provides resources for projects focused on developing therapies for unmet needs that are not adequately addressed by the private sector.


Partnership to Develop Novel Treatment Approaches

On March 18th, Boehringer Ingelheim and Vanderbilt University announced a collaboration to fight cancer through the licensing of a drug discovery program that matured in the NCI Experimental Therapeutics (NExT) program. The Fesik laboratory at Vanderbilt University in collaboration with the Chemical Biology Consortium made impressive strides in developing inhibitors of Mcl-1. The partnership with Boehringer Ingelheim will facilitate the advancement of these promising therapeutics towards clinical development with the potential of delivering a new cancer drug to market.